Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd (SHE:301130)
China · Delayed Price · Currency is CNY 26.52
-1.10 (-3.98%)
Sep 10, 2026, 3:04 PM CST
SHE:301130 Revenue
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd had revenue of 45.50M CNY in the quarter ending June 30, 2026, a decrease of -40.20%. This brings the company's revenue in the last twelve months to 207.96M, down -18.69% year-over-year. In the year 2025, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd had annual revenue of 234.84M, down -8.41%.
Revenue (ttm)
207.96M
Revenue Growth
-18.69%
P/S Ratio
10.03
Revenue / Employee
664.40K
Employees
313
Market Cap
2.09B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 234.84M | -21.56M | -8.41% |
| Dec 31, 2024 | 256.41M | 30.91M | 13.71% |
| Dec 31, 2023 | 225.49M | -29.98M | -11.73% |
| Jan 1, 2023 | 255.47M | -30.19M | -10.57% |
| Jan 1, 2022 | 285.66M | -662.79K | -0.23% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 849.67M |
| Zhejiang Shengda Bio-Pharm | 832.86M |
| Enwei Pharmaceutical | 826.13M |
| Hainan Huluwa Pharmaceutical Group | 634.04M |
| Chengdu huasun technology group Inc. , LTD. | 486.70M |
| Zhejiang Shapuaisi Pharmaceutical | 423.20M |
| Anhui Huangshan Capsule | 407.10M |
| Guhan Pharmaceutical Group | 329.41M |